CNMD

Conmed Corp

Add to Watchlist

Advanced Chart

53.710

+1.23(2.344%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

53.940

Open

52.810

VWAP

53.40

Vol

69.38K

Mkt Cap

1.62B

Low

52.810

Amount

3.70M

EV/EBITDA(TTM)

10.09

Total Shares

30.80M

2.47B

EV/OCF(TTM)

14.97

P/S(TTM)

1.23

CONMED Corporation is a medical technology company, which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

339.53M

+5.69%

1.020

+7.37%

369.10M

+6.69%

1.318

-1.65%

334.76M

+5.7%

1.052

+0.2%

Estimates Revision

The market is revising Downward the revenue expectations for CONMED Corporation (CNMD) for FY2025, with the revenue forecasts being adjusted by -0.03% over the past three months. During the same period, the stock price has changed by -11.56%.

Revenue Estimates for FY2025

Revise Downward

-0.03%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-11.56%

In Past 3 Month

2 Analyst Rating

26.61% Upside

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 68.00 USD with a low forecast of 68.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

26.61% Upside

Current: 53.710

Low

68.00

Averages

68.00

High

68.00

26.61% Upside

Current: 53.710

Low

68.00

Averages

68.00

High

68.00

Needham

Buy

Hold

downgrade

2025-06-12

Reason

Needham

Price Target

2025-06-12

downgrade

Buy

Hold

Reason

Needham downgraded Conmed to Hold from Buy without a price target. The company's long-term growth rate has decreased, mainly due to slower AirSeal and Buffalo Filter growth, the analyst tells investors in a research note. The firm believes the slower revenue growth is likely to drive more gradual margin improvement and slower earnings growth at Conmed. In addition, the company's debt level limits its ability to acquire new growth drivers or to repurchase shares, contends Needham. The firm says Conmed's outlook has deteriorated while the shares no longer at a discount given that peer multiples have contracted.

JP Morgan

Robbie Marcus

Buy

Hold

Downgrades

$85 → $70

2025-02-06

Reason

JP Morgan

Robbie Marcus

Price Target

$85 → $70

2025-02-06

Downgrades

Buy

Hold

Reason

Needham

Mike Matson

Strong Buy

Maintains

$97 → $91

2025-02-06

Reason

Needham

Mike Matson

Price Target

$97 → $91

2025-02-06

Maintains

Strong Buy

Reason

Wells Fargo

Vik Chopra

Hold

Maintains

$74 → $70

2025-02-06

Reason

Wells Fargo

Vik Chopra

Price Target

$74 → $70

2025-02-06

Maintains

Hold

Reason

Stifel

Rick Wise

Strong Buy

Maintains

$72 → $75

2025-02-06

Reason

Stifel

Rick Wise

Price Target

$72 → $75

2025-02-06

Maintains

Strong Buy

Reason

Needham

Mike Matson

Strong Buy

Reiterates

$97

2024-10-31

Reason

Needham

Mike Matson

Price Target

$97

2024-10-31

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Conmed Corp (CNMD.N) is 11.56, compared to its 5-year average forward P/E of 28.21. For a more detailed relative valuation and DCF analysis to assess Conmed Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

28.21

Current PE

11.56

Overvalued PE

38.59

Undervalued PE

17.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

16.29

Current EV/EBITDA

8.90

Overvalued EV/EBITDA

20.63

Undervalued EV/EBITDA

11.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.54

Current PS

1.20

Overvalued PS

3.40

Undervalued PS

1.68